NCT06189391 2026-03-17
MK-1045-001
MSD R&D (China) Co., Ltd.
Phase 1 Recruiting
Clinical Trials
543 trialsNCT07156565 2026-03-17
ATLAS
Ratio Therapeutics, Inc.
Phase 1 Recruiting
NCT07164560 2026-03-17
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Recruiting
NCT03742245 2026-03-16
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT04926285 2026-03-16
VEN-OM
University of Illinois at Chicago
Phase 1 Completed
NCT07137494 2026-03-16
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07297979 2026-03-16
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Amgen
Phase 1 Recruiting
NCT03460977 2026-03-13
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
NCT05652335 2026-03-13
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06425991 2026-03-13
MajesTEC-10
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06604715 2026-03-13
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05748197 2026-03-10
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07257419 2026-03-10
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT06375044 2026-03-06
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06508138 2026-03-06
J21112LINKED
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Enrolling by invitation
NCT05927571 2026-03-05
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Recruiting
NCT07280013 2026-03-05
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
C4 Therapeutics, Inc.
Phase 1 Recruiting
NCT06321484 2026-03-04
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06868433 2026-03-04
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Emory University
Phase 1 Recruiting
NCT06846606 2026-03-03
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics, Inc.
Phase 1 Active not recruiting
NCT03939026 2026-03-02
ALPHA
Allogene Therapeutics
Phase 1 Completed
NCT06173518 2026-03-02
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
Phase 1 Recruiting
NCT05815160 2026-02-27
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Debiopharm International SA
Phase 1 Active not recruiting
NCT02926690 2026-02-25
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
OncoTherapy Science, Inc.
Phase 1 Recruiting
NCT04279847 2026-02-25
LIMBER
Incyte Corporation
Phase 1 Active not recruiting
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT05537740 2026-02-23
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
Phase 1 Active not recruiting
NCT07428486 2026-02-23
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT05527184 2026-02-20
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
Phase 1 Active not recruiting
NCT07424833 2026-02-20
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Phase 1 Not yet recruiting
NCT04619056 2026-02-19
First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
CEBIOTEX
Phase 1 Completed
NCT06863259 2026-02-18
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Children's Hospital Medical Center, Cincinnati
Phase 1 Recruiting
NCT07113691 2026-02-17
TIARA
Yale University
Phase 1 Recruiting
NCT05079282 2026-02-13
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co. Ltd
Phase 1 Recruiting
NCT06325748 2026-02-12
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
Phase 1 Active not recruiting
NCT03029338 2026-02-11
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT04155749 2026-02-11
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Gilead Sciences
Phase 1 Active not recruiting
NCT04690595 2026-02-11
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
PeproMene Bio, Inc.
Phase 1 Active not recruiting
NCT07015697 2026-02-10
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT06215118 2026-02-05
MagnetisMM-30
Pfizer
Phase 1 Recruiting
NCT06565689 2026-02-05
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Excyte Biopharma Ltd
Phase 1 Recruiting
NCT06574568 2026-02-05
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd
Phase 1 Recruiting
NCT06880549 2026-02-05
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT02651662 2026-02-02
CLIO-1
Regeneron Pharmaceuticals
Phase 1 Active not recruiting
NCT00709033 2026-01-30
ATECRAB
Baylor College of Medicine
Phase 1 Completed
NCT05184816 2026-01-30
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04150042 2026-01-29
SHARON
General Oncology, Inc.
Phase 1 Recruiting
NCT05787496 2026-01-28
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Phase 1 Terminated
NCT05753501 2026-01-27
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
Phase 1 Recruiting